Trial Profile
A Phase 1 Study of PARP Inhibitor BMN 673 and HSP90 Inhibitor AT13387 for Treatment of Advanced Solid Tumors With Expansion in Patients With Recurrent Epithelial Ovarian, Fallopian Tube, Peritoneal Cancer or Recurrent Triple-Negative Breast Cancer
Status:
Withdrawn prior to enrolment
Phase of Trial:
Phase I
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Onalespib (Primary) ; Talazoparib (Primary)
- Indications Breast cancer; Fallopian tube cancer; Male breast cancer; Ovarian cancer; Peritoneal cancer; Triple negative breast cancer
- Focus Adverse reactions
- 22 Jul 2016 Status changed from not yet recruiting to withdrawn prior to enrolment.
- 15 Dec 2015 New trial record